Last reviewed · How we verify
l-LV (dl-LV)
l-LV (dl-LV) is a Amino acid derivative Small molecule drug developed by Epidemiological and Clinical Research Information Network. It is currently in Phase 3 development for Treatment of various cancers. Also known as: Leucovorin.
L-LV is a synthetic amino acid derivative that acts as a competitive inhibitor of the enzyme leucine aminopeptidase.
L-LV is a synthetic amino acid derivative that acts as a competitive inhibitor of the enzyme leucine aminopeptidase. Used for Treatment of various cancers.
At a glance
| Generic name | l-LV (dl-LV) |
|---|---|
| Also known as | Leucovorin |
| Sponsor | Epidemiological and Clinical Research Information Network |
| Drug class | Amino acid derivative |
| Target | Leucine aminopeptidase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
L-LV works by competitively inhibiting leucine aminopeptidase, an enzyme involved in the breakdown of amino acids. This inhibition leads to an accumulation of leucine in the body, which has various effects on cellular metabolism and function.
Approved indications
- Treatment of various cancers
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer
- Characterization of priMary And sEcondary STress Related takOtsubo (NA)
- FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma (PHASE2)
- Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer (PHASE2)
- A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC (PHASE3)
- A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC (PHASE3)
- RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301). (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- l-LV (dl-LV) CI brief — competitive landscape report
- l-LV (dl-LV) updates RSS · CI watch RSS
- Epidemiological and Clinical Research Information Network portfolio CI
Frequently asked questions about l-LV (dl-LV)
What is l-LV (dl-LV)?
How does l-LV (dl-LV) work?
What is l-LV (dl-LV) used for?
Who makes l-LV (dl-LV)?
Is l-LV (dl-LV) also known as anything else?
What drug class is l-LV (dl-LV) in?
What development phase is l-LV (dl-LV) in?
What are the side effects of l-LV (dl-LV)?
What does l-LV (dl-LV) target?
Related
- Drug class: All Amino acid derivative drugs
- Target: All drugs targeting Leucine aminopeptidase
- Manufacturer: Epidemiological and Clinical Research Information Network — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Treatment of various cancers
- Also known as: Leucovorin
- Compare: l-LV (dl-LV) vs similar drugs
- Pricing: l-LV (dl-LV) cost, discount & access